Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 7/20 | 0.69 |
| ▸ | CTSB | P07858 | 5/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6229384 | 0.86 | CTSL (0.68) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL2675573 | 0.86 | CTSL (0.73) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL27647421 | 0.85 | CTSL (0.71) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL27627084 | 0.83 | CTSL (0.69) | CTSLCTSBATMMETTL3MAPT | |
| SCHEMBL8320462 | 0.83 | CTSL (0.69) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL27647321 | 0.83 | CTSL (0.69) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL8320460 | 0.83 | CTSL (0.69) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL7167509 | 0.82 | CTSL (0.68) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL7167512 | 0.82 | CTSL (0.68) | CTSLCTSBATMMETTL3GAA | |
| SCHEMBL27999578 | 0.81 | CTSL (0.70) | CTSLCTSBATMMETTL3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173696-B2 | Inhibitors of cysteine proteases and methods of use thereof | BAYLOR UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | BAYLOR UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSB, CTSS, CTSZ | CTSL 6/4885CTSB 1/4885ATM 3439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.